3BIGS CO., LTD.’s Post

3BIGS’ cosmetic peptide sets foot. An atopic lesion improving peptide can now be used in cosmetic formulation to heal skin injury and as skin protection. This is achieved by the gain of INCI name (International Nomenclature Cosmetic Ingredient) and its registration in International Cosmetic Ingredient Dictionary and Handbook. INCI names are internationally recognized systematic nomenclature to identify cosmetic ingredients. It is designated by the International Cosmetic Ingredient Nomenclature Committee (INC) and published by Personal Care Products Council (PCPC). We are happy to get recognition after rigorous screening to ensure the safety and quality of cosmetic peptide. #3BIGS_Cosmetic_Peptide #INCI #INC #PCPC #Atopicpeptide #Skin_peptide

Crohn’s disease and ulcerative colitis collectively termed inflammatory bowel disease (IBD) is an autoimmune disorder affecting gut health. Although the exact causal factor for the condition is unknown, the mainstay medication relies majorly on immunosuppressants, anti-inflammatory drugs, biologics and steroids to halt/reduce the inflammation and flare ups. 3BIGS is excited to share the identification of anti-inflammatory peptide that targets TNF-α for the treatment of IBD, utilizing its bio big data guided AI pipeline. TNF-α is the main cytokine mediator responsible for the chronic inflammation and tissue damage observed in IBD. TNF targeting biologics revolutionized IBD treatment along with conventional therapy. Peptide drugs has an advantage of lesser production cost, no immunogenicity, more stable molecule than biologics. Promising results from the pre-clinical studies of 3BIGS’ TNF targeting peptide encourage us to move forward to the next phase of peptide drug development. #IBD #colitis #TNFtargetingpeptide #peptidedrug #antiinflammatories #antiTNF #biobigdata #AI

Porphyromonas gingivalis is a pathogenic gram negative anaerobic bacteria that can colonize in the oral cavity, causing a bacterially induced inflammatory disease defined as periodontal disease. Oral and/or topical antibiotics might be used to control or treat infection in addition to nonsurgical interventions like scaling and root planing. But the overuse or misuse of antibiotics could be attributed to the emergence of antibiotic resistance P. gingivalis strain. To prevent this, 3BIGS Co. Ltd. has successfully identified an antibacterial peptide which has excellent antibacterial activity against P. gingivalis. The invention is patent registered in the Korean Intellectual Property office. The peptide is effective against P. gingivalis at minimal concentration than the regular dose of antibiotics. Notably, the peptide exhibited no cytotoxicity in normal epidermal phenotype present in the oral mucosa at the concentration needed for anti P. gingivalis activity as well as higher concentrations. Taken together, this peptide has good antibacterial activity with no cytotoxicity. Several scientific studies have investigated the link between periodontal disease and Alzheimer’s disease (AD). P. gingivalis, the periodontal pathogens were detected in the AD brain and the chronic inflammatory nature of periodontitis exacerbate the inflammatory process in the AD brain. So, we intend to propose the usage of 3BIGS anti P. gingivalis peptide both in the prevention and treatment of periodontal disease and Alzheimer's disease. Stay connected to #3BIGS to know about the discovery and development of 3BIGS’ antimicrobial peptides. #3BIGS #antibacterialpeptide #Pgingivalis #periodontaldisease #Alzheimers #gingivitis #periodontitis